<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00801281</url>
  </required_header>
  <id_info>
    <org_study_id>R-CVP/CHOP</org_study_id>
    <nct_id>NCT00801281</nct_id>
  </id_info>
  <brief_title>First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.</brief_title>
  <acronym>PLRG4</acronym>
  <official_title>First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.A Multicentre, Phase III Randomized Study by the PLRG.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polish Lymphoma Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Polish Lymphoma Research Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of event free survival (EFS) of patients treated with the study chemotherapy
      induction program: R-CHOP compared to the standard R-CVP regimen and response rates, time to
      best response, PFS, OS, neutropenic fever rate, infection rate, change in Ig levels, change
      in lymphocyte subpopulations counts in previously untreated indolent lymphoma patients in
      need of systemic treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Min. 3, max. 8 induction cycles. Maintenance with rituximab q. 2 months x 12/24 months,
      started 2 months after last chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">June 25, 2017</completion_date>
  <primary_completion_date type="Actual">June 25, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival</measure>
    <time_frame>+3 yrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>+2 yrs</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Follicular Lymphoma</condition>
  <condition>Marginal Zone Lymphoma</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <condition>Lymphoplasmacytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>R-CVP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard arm 1. R-CVP - Rituximab, Cyclophosphamide, Vincristine, Prednisone 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-CHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study arm 2. R-CHOP - Rituximab, Cyclophosphamide, Hydroxyldaunorubicine (doxorubicin), Oncovin (vincristine), Prednisone 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab 375 mg/m2 i.v. d. 1 q. 21 d.</description>
    <arm_group_label>R-CVP</arm_group_label>
    <arm_group_label>R-CHOP</arm_group_label>
    <other_name>MabThera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 750 mg/m2 i.v. d. 1 q. 21 d.</description>
    <arm_group_label>R-CVP</arm_group_label>
    <arm_group_label>R-CHOP</arm_group_label>
    <other_name>Endoxan, Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin 50 mg/m2 i.v. d. 1 q. 21 d.</description>
    <arm_group_label>R-CHOP</arm_group_label>
    <other_name>Adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Vincristine 1.4 mg/m2 (max. 2 mg) i.v. d. 1 q. 21 d.</description>
    <arm_group_label>R-CVP</arm_group_label>
    <arm_group_label>R-CHOP</arm_group_label>
    <other_name>Oncovin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone 1</intervention_name>
    <description>Prednisone 100 mg p.o. d. 1-5 q. 21 d.</description>
    <arm_group_label>R-CHOP</arm_group_label>
    <other_name>Deltasone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone 2</intervention_name>
    <description>Prednisone 40 mg/m2 p.o. d. 1-5 q. 21 d.</description>
    <arm_group_label>R-CVP</arm_group_label>
    <other_name>Deltasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed:

          -  Follicular lymphoma grade 1, 2, 3a

          -  Marginal zone lymphoma, including MALT type

          -  Small lymphocytic lymphoma (BM inv. &lt; 30%)

          -  Lymphoplasmacytic lymphoma

          -  Clinical stage II-IV (Ann Arbor). Stage I is allowed if bulky (Ø &gt; 7 cm) or if
             radiotherapy is not appropriate in judgment of treating physician

          -  Measurable lesion(s) in at least one site

          -  Patients previously untreated

          -  Patients presenting with symptoms requiring treatment:

          -  Progressive disease

          -  Symptoms related to tumor bulk

          -  Cytopenias related to bone marrow and/or spleen involvement B symptoms

          -  Age ≥ 18 years

          -  Performance status &lt;/=2

          -  Written informed consent

        Exclusion Criteria:

          -  Grade 3b FL

          -  Transformed lymphoma

          -  CNS involvement

          -  Patient taking steroids for &gt; 2 weeks during last 4 weeks at a dose equivalent to ≥ 20
             mg prednisone

          -  Other malignancy

          -  Major surgery within 4 weeks

          -  Hb &lt; 8 g/dl, ANC &lt; 1.5 x 109/L, Plt &lt;100 109/L unless due to lymphoma

          -  Impairment of renal function (creatinine &gt; 1.5 x UNV) or liver function (total
             bilirubin 1.5 x UNV, SGOT &gt; 2.5 x UNV not due to lymphoma

          -  Known infection, with HBV, HCV (acute &lt; 6 mos. or chronic hepatitis) or HIV

          -  Serious underlying medical conditions

          -  Life expectancy &lt; 6 months

          -  Known allergy to murine protein
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan A Walewski, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vice-president of PLRG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Podolak-Dawidziak, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>PLRG Board Member</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Beata Stella-Hołowiecka, Assoc. Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>PLRG Member</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Podkarpacki Oncology Centre</name>
      <address>
        <city>Brzozów</city>
        <zip>36-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Voivodeship Hospital, Oncology Ward</name>
      <address>
        <city>Elbląg</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Clinical Centre, Hospital of Medical Academy, Clinic of Haematology and Transplantology</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silesian Medical University, Chair and Clinic of Haematology and Bone Marrow Transplantation</name>
      <address>
        <city>Katowice</city>
        <zip>40-029</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collegium Medicum Jagiellonian University, Clinic of Haematology</name>
      <address>
        <city>Kraków</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Centre of Lublin Region</name>
      <address>
        <city>Lublin</city>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital, Ministry of Internal Matters and Administration; Clinic of Oncology, Haematology and Internal Diseases</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Haematology and Transfusiology</name>
      <address>
        <city>Warszawa</city>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.Sklodowska-Curie Institute - Oncology Centre</name>
      <address>
        <city>Warszawa</city>
        <zip>02-782</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Academy in Wrocław; Chair and Clinic of Haematology, Blood Neoplasm and Bone Marrow Transplantation</name>
      <address>
        <city>Wrocław</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP ZOZ Silesian Centre of Cellular Transplantation</name>
      <address>
        <city>Wrocław</city>
        <zip>53-439</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Oncology Centre, Ward of Proliferative Diseases</name>
      <address>
        <city>Łódź</city>
        <zip>93-509</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>http://www.plrg.coi.pl</url>
    <description>Click here to provide more information about this study: PLRG4</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2008</study_first_submitted>
  <study_first_submitted_qc>December 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2008</study_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Immunochemotherapy</keyword>
  <keyword>Induction therapy</keyword>
  <keyword>Maintenance therapy</keyword>
  <keyword>Follicular lymphoma grade 1,2,3a</keyword>
  <keyword>Marginal zone lymphoma, including MALT type</keyword>
  <keyword>Small lymphocytic lymphoma (BM inv. &lt;30%)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

